TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30612202

Group type: EXPERIMENTAL
Intervention: Low glycemic index diet (EX-LOG: 40 ± 0.3 au)
Number of subjects: 33

Group type: COMPARATOR
Intervention: High glycemic index diet (EX-HIG: 80 ± 0.6 au)
Number of subjects: 33
Study: 27522095

Group type: EXPERIMENTAL
Intervention: Spot fluoroscopy (SF)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional fluoroscopy (CF)
Number of subjects: 35
Study: 24990113

Group type: EXPERIMENTAL
Intervention: Crizotinib (Xalkori®)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 2

Group type: COMPARATOR
Intervention: Formulations (powder in capsule [PIC], immediate-release tablet [IRT], commercial formulated capsule [FC])
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 2
Study: 22384983

Group type: EXPERIMENTAL
Intervention: Moisturizing lotion (Cetaphil®) + adapalene gel 0.1%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adapalene gel 0.1% only
Number of subjects: 30
Study: 20864883

Group type: EXPERIMENTAL
Intervention: MS‐sNT (morphine sulfate and naltrexone hydrochloride extended release capsules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: KADIAN® (morphine sulfate extended release capsules)
Number of subjects: 0
Study: 19769799

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control acupuncture
Number of subjects: 24
Study: 16619656

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15134124

Group type: EXPERIMENTAL
Intervention: Verbal-direct strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal-indirect strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonverbal-indirect strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culturally sensitive HIV prevention strategies
Number of subjects: 0
Study: 11531033

Group type: EXPERIMENTAL
Intervention: Jogging shod (with athletic shoes)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Jogging unshod (barefoot)
Number of subjects: 12
Study: 9000664

Group type: EXPERIMENTAL
Intervention: CsA
Number of subjects: 29

Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: CsA 2
Number of subjects: 29

Group type: COMPARATOR
Intervention: FK506
Number of subjects: 29
Study: 7719680

Group type: EXPERIMENTAL
Intervention: Gastromiro
Number of subjects: 150

Group type: COMPARATOR
Intervention: Urografin 370 (diatrizoate)
Number of subjects: 150

Group type: COMPARATOR
Intervention: E-Z CAT (barium sulphate)
Number of subjects: 150
Study: 2883837

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: EA + naloxone (0.8 mg IM)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: EA + placebo
Number of subjects: 5
Study: 29428844

Group type: COMPARATOR
Intervention: Control (no treatment; n = 17)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: eCG (300 IU i.m.; n = 17)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: hCG 300 (300 IU i.m.; n = 18)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: hCG 200 IM (200 IU i.m.; n = 16)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: hCG 200 SC (200 IU s.c.; n = 16)
Number of subjects: 84
Study: 27632079

Group type: EXPERIMENTAL
Intervention: 3D template model
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2D template
Number of subjects: 40
Study: 24879167

Group type: COMPARATOR
Intervention: Lido-S (lidocaine instillation and saline in the cuff)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lido-Lido (lidocaine instillation and lidocaine in the cuff)
Number of subjects: 80

Group type: COMPARATOR
Intervention: S-S (Saline instillation and saline in the cuff)
Number of subjects: 80

Group type: COMPARATOR
Intervention: S-Lido (saline instillation and lidocaine in the cuff)
Number of subjects: 80
Study: 22817340

Group type: EXPERIMENTAL
Intervention: Automated closed-loop (CL) system started at 18:00 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Automated closed-loop (CL) system started at 21:00 hours
Number of subjects: 8
Study: 20053810

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral carotid artery stenting (SBCAS)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Unilateral carotid artery stenting (CAS)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: SBCAS
Number of subjects: 205

Group type: COMPARATOR
Intervention: Unilateral CAS
Number of subjects: 205
Study: 18678119

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 3 units (600 ml) of fresh frozen plasma (FFP) over 90 minutes
Number of subjects: 109

Group type: COMPARATOR
Intervention: Intravenous infusion of isotonic saline over 90 minutes
Number of subjects: 109
Study: 15601734

Group type: EXPERIMENTAL
Intervention: Unilateral clicks (0.1 ms, 3 Hz, 70‐100 dB NHL) during steady masseter contraction
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Loud clicks at 100 dB
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Higher-intensity clicks
Number of subjects: 18
Study: 12133885

Group type: EXPERIMENTAL
Intervention: Dynamic colostrum (20 g daily for 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (20 g maltodextrin daily for 2 weeks)
Number of subjects: 30
Study: 10467919

Group type: EXPERIMENTAL
Intervention: Antidepressants prescribed to women with non-cancer pain
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Psychosocial and behavioral characteristics in non-cancer pain patients
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Pain severity, mood, and disability in cancer pain patients
Number of subjects: 571

Group type: COMPARATOR
Intervention: Comparison of treatment history and current analgesic use in non-cancer pain patients
Number of subjects: 571

Group type: COMPARATOR
Intervention: Comparison of treatment variables in cancer pain patients
Number of subjects: 571
Study: 7783656

Group type: EXPERIMENTAL
Intervention: 0.05 IU/kg/d rHGH
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.1 IU/kg/d rHGH
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg/d rHGH
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2212391

Group type: EXPERIMENTAL
Intervention: Vitamin C restriction with a daily intake of 25 mg/day (after 3 weeks of low intake)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group with the same diet supplemented with twice the RDA for all vitamins
Number of subjects: 12
Study: 627883

Group type: EXPERIMENTAL
Intervention: Methadone 40 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methadone 80 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Heroin (0.214 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30066392

Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 1386

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 1386
Study: 29112070

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitor (PI/r)
Number of subjects: 415
Study: 25162212

Group type: EXPERIMENTAL
Intervention: IL-2 receptor antagonists (IL-2RAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: rabbit anti-thymocyte globulin (rATG)
Number of subjects: 0
Study: 23511114

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 1306

Group type: COMPARATOR
Intervention: Scleral buckling (SB)
Number of subjects: 1306
Study: 21099672

Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 1824

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 1824
Study: 18986600

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 16895939

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Monitoring of ALT and haemoglobin
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Yearly monitoring of triglycerides, cholesterol, glucose and creatinine
Number of subjects: 417
Study: 15523452

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (1 mg/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 11718271

Group type: EXPERIMENTAL
Intervention: Protocol A: DTX (80 mg/m2) followed by VNR (25 mg/m2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Protocol B: VNR (25 mg/m2) followed by DTX (80 mg/m2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Protocol A
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Protocol B
Number of subjects: 23
Study: 9850014

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CEF: cyclophosphamide 500 mg/m2, epirubicin 60 mg/m2, fluorouracil 500 mg/m2)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Single-agent epirubicin (20 mg/m2) followed by single-agent mitomycin (8 mg/m2)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Single-agent mitomycin (8 mg/m2)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CEF) followed by mitomycin and vinblastine (MV)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CEF)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Single-agent therapy
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 303
Study: 8014492

Group type: EXPERIMENTAL
Intervention: ethambutol (15 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: clofazimine (200 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rifampin (600 mg)
Number of subjects: 60
Study: 2509917

Group type: EXPERIMENTAL
Intervention: Interferon alfa (2 million units) subcutaneously three times weekly for six months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 786350

Group type: EXPERIMENTAL
Intervention: Controlled ventilation technique using nitrous oxide and oxygen, with tubocurarine and fentanyl
Number of subjects: 2

Group type: COMPARATOR
Intervention: Spontaneous ventilation technique using nitrous oxide, oxygen and halothane
Number of subjects: 2
Study: 31185058

Group type: EXPERIMENTAL
Intervention: Specialist contraceptive support via telephone or face-to-face consultation at 2–4 weeks and 3 months post-abortion
Number of subjects: 569

Group type: COMPARATOR
Intervention: Standard care (advice to follow up with general practitioner or contraceptive clinic)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Specialist contraceptive support
Number of subjects: 569

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 569
Study: 29125703

Group type: EXPERIMENTAL
Intervention: Mavatrep (JNJ-39439335) 10 mg single dose
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mavatrep (JNJ-39439335) 25 mg single dose
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mavatrep (JNJ-39439335) 50 mg single dose
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mavatrep (JNJ-39439335) once-daily 10 mg for 21 days
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mavatrep (JNJ-39439335) once-daily 25 mg for 21 days
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mavatrep (JNJ-39439335) once-daily 50 mg for 21 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 29786223

Group type: EXPERIMENTAL
Intervention: Percutaneous Compression Plate (PCCP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Hollow Compression Screw
Number of subjects: 70
Study: 25319690

Group type: EXPERIMENTAL
Intervention: Positive emotional pictures
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Negative emotional pictures
Number of subjects: 586

Group type: COMPARATOR
Intervention: Neutral pictures
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Hippocampus to amygdala connection
Number of subjects: 586
Study: 22205605

Group type: EXPERIMENTAL
Intervention: CsA eye drops for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artificial tears (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CsA in compartmental culture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle in compartmental culture (Control)
Number of subjects: 0
Study: 19615755

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Group-based trajectory modeling
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Brief screening for maternal depressive symptoms
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 181
Study: 16806740

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 51
Study: 16226044

Group type: EXPERIMENTAL
Intervention: Complete androgen blockade initiated 2 months prior to starting radiotherapy and stopped at the completion of radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant androgen suppression started at the end of the radiotherapy and continued indefinitely
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete androgen blockade for two months before and during radiation followed by 24 additional months of LHRH analogue alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androgen suppression with LHRH analogue given during and for 3 years after external irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormonal treatment in localized prostate cancer (T1‐2 N0) with poor prognostic factors: Gleason score 8‐10, PSA>20 ng/ml
Number of subjects: 0
Study: 12365874

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10464863

Group type: EXPERIMENTAL
Intervention: Haemodialysis patients (HDp)
Number of subjects: 29

Group type: COMPARATOR
Intervention: PPD (‐) HDp
Number of subjects: 29

Group type: COMPARATOR
Intervention: PPD (+) HDp
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nutritional parameters
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PBL subtype percentages and absolute counts
Number of subjects: 29
Study: 7793217

Group type: EXPERIMENTAL
Intervention: ketobemidone 5 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: lorazepam 1 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: propranolol 40 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study: 1778085

Group type: COMPARATOR
Intervention: Chlorthalidone (25 mg)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus Triamterene (25 mg + 50 mg)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Crossover from Chlorthalidone plus Triamterene to Chlorthalidone
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Crossover from Chlorthalidone to Chlorthalidone plus Triamterene
Number of subjects: 129
Study: 7249547

Group type: EXPERIMENTAL
Intervention: DL-propranolol (0.1 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-propranolol (1.0 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DL-propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DL-propranolol and D-propranolol
Number of subjects: 0
Study: 6339649

Group type: EXPERIMENTAL
Intervention: Ticarcillin-tobramycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azlocillin-tobramycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azlocillin-placebo
Number of subjects: 0
Study: 30629024

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 861

Group type: COMPARATOR
Intervention: gemcitabine alone
Number of subjects: 861
Study: 31065119

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dexmedetomidine 10 micrograms
Number of subjects: 60
Study: 26673802

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.5 mcg kg⁻¹
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palonosetron 1.0 mcg kg⁻¹
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palonosetron 1.5 mcg kg⁻¹
Number of subjects: 0
Study: 24623515

Group type: EXPERIMENTAL
Intervention: Nature walking route (NW)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Built walking route (BW)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combined groups (NW and BW)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study: 22353042

Group type: EXPERIMENTAL
Intervention: Melamine foam sponge
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cotton wool bud
Number of subjects: 27
Study: 20004526

Group type: EXPERIMENTAL
Intervention: Dose outside the prostate (68-78 Gy)
Number of subjects: 352
Study: 17425493

Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet and antithrombotic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfusion therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pediatric arterial ischemic stroke studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: International study
Number of subjects: 0
Study: 15657070

Group type: EXPERIMENTAL
Intervention: Injection of triamcinolone 20 mg and eight sessions of standardized physiotherapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Injection of triamcinolone 20 mg alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo injection and eight sessions of standardized physiotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo injection alone
Number of subjects: 80
Study: 12651995

Group type: EXPERIMENTAL
Intervention: Active support
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Passive support
Number of subjects: 101

Group type: COMPARATOR
Intervention: Alone
Number of subjects: 101

Group type: COMPARATOR
Intervention: Interaction
Number of subjects: 101
Study: 10592533

Group type: EXPERIMENTAL
Intervention: Amtolmetina guacyl (Eufans) 600 mg once daily for 14 consecutive days per month for 2 months (P, n = 10; PV, n = 8; PVE, n = 7)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No treatment (matched-control, n = 6 for each category)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Amtolmetina guacyl treatment (after first course T1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Amtolmetina guacyl treatment (after second course T2)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Amtolmetina guacyl treatment (T2)
Number of subjects: 43
Study: 8708166

Group type: COMPARATOR
Intervention: Normal Saline (NS) 100 cc with Unweighted tube (UNW)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Normal Saline (NS) 100 cc with Weighted tube (WEI)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Erythromycin (EMY) 200 mg with Weighted tube (WEI)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Metoclopramide (MET) 10 mg with Weighted tube (WEI)
Number of subjects: 83
Study: 2036759

Group type: EXPERIMENTAL
Intervention: Sodium iothalamate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium/methylglucamine ioxaglate
Number of subjects: 0
Study: 7041039

Group type: EXPERIMENTAL
Intervention: Vitamin E treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study: 31747009

Group type: EXPERIMENTAL
Intervention: Depatux‐M 1.25 mg/kg every 2 weeks intravenously
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Depatux‐M monotherapy
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Combination of Depatux‐M with temozolomide
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control arm (temozolomide or lomustine)
Number of subjects: 260
Study: 31570211

Group type: EXPERIMENTAL
Intervention: Body weight support-Tai Chi (BWS-TC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 27859645

Group type: EXPERIMENTAL
Intervention: Ultrathin colonoscope (UTC)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Pediatric colonoscope (PDC)
Number of subjects: 77
Study: 26507718

Group type: EXPERIMENTAL
Intervention: Operative treatment (surgery using tension band wiring or plate fixation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-operative treatment (early range of motion as tolerated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 0
Study: 23674047

Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional-reperfusion
Number of subjects: 39
Study: 21546857

Group type: EXPERIMENTAL
Intervention: Interferon-α (IFN)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 117
Study: 20040824

Group type: EXPERIMENTAL
Intervention: Atomoxetine hydrochloride
Number of subjects: 714
Study: 17696259

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg/d
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lamivudine (LVD) 100 mg/d
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lamivudine (LVD) switched to Entecavir (ETV) 1.0 mg/d
Number of subjects: 61
Study: 15145968

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg) 1-minute infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg) 1-hour infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg) 3-hour infusion
Number of subjects: 8
Study: 11444340

Group type: EXPERIMENTAL
Intervention: Misoprostol (n=30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: PG F2alpha (n=31)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 10363123

Group type: EXPERIMENTAL
Intervention: Transcervical intrafallopian insemination (IFI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI)
Number of subjects: 30
Study: 7491044

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 MU intravenous infusion for 1 hour)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Streptokinase plus aspirin
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/day for 10 days)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Neither treatment (control group)
Number of subjects: 622